Despite efforts to stay alive and attract more funding, Cogent Neuroscience has filed Chapter 7 bankruptcy and plans to liquidate.

In October, Cogent sent its 48 remaining employees home, as the company’s board and investors explored ways to configure the company to survive in this market.

Cogent failed to land a much-needed fourth round of from $15 to $25 million. As the Durham-based drug discover company ran short of cash, its backers refused to provide more money.

Now some of them, including Intersouth and Durham-based Aurora Funds, are listed as creditors.